KR20060070572A - Hsp90-저해제로서의 신규 헤테로시클릭 화합물 - Google Patents
Hsp90-저해제로서의 신규 헤테로시클릭 화합물 Download PDFInfo
- Publication number
- KR20060070572A KR20060070572A KR1020067007478A KR20067007478A KR20060070572A KR 20060070572 A KR20060070572 A KR 20060070572A KR 1020067007478 A KR1020067007478 A KR 1020067007478A KR 20067007478 A KR20067007478 A KR 20067007478A KR 20060070572 A KR20060070572 A KR 20060070572A
- Authority
- KR
- South Korea
- Prior art keywords
- aryl
- heteroaryl
- compound
- pharmaceutically acceptable
- substituents
- Prior art date
Links
- 0 **N(C(*)=C(*)C1=C(*)*)C1=*C(*)=I Chemical compound **N(C(*)=C(*)C1=C(*)*)C1=*C(*)=I 0.000 description 17
- QIOVDTJAHJLIII-UHFFFAOYSA-N CC(C)(C)C(Nc1nc(Cl)c(c(I)c[n]2Cc3ncc(C)c(Cl)c3C)c2n1)=O Chemical compound CC(C)(C)C(Nc1nc(Cl)c(c(I)c[n]2Cc3ncc(C)c(Cl)c3C)c2n1)=O QIOVDTJAHJLIII-UHFFFAOYSA-N 0.000 description 1
- RMNGRTOATWLDLK-UHFFFAOYSA-N CCC(c(c(NCc(c(C)c1I)ncc1N)nc(N)n1)c1Cl)=[IH] Chemical compound CCC(c(c(NCc(c(C)c1I)ncc1N)nc(N)n1)c1Cl)=[IH] RMNGRTOATWLDLK-UHFFFAOYSA-N 0.000 description 1
- LWAABEQBZKOASJ-UHFFFAOYSA-N CCc1c[n](Cc2c(C)c(OC)c(C)cn2)c2nc(N)nc(Cl)c12 Chemical compound CCc1c[n](Cc2c(C)c(OC)c(C)cn2)c2nc(N)nc(Cl)c12 LWAABEQBZKOASJ-UHFFFAOYSA-N 0.000 description 1
- CWDAXYXBEUCCII-UHFFFAOYSA-N CCc1c[n](Cc2ncc(C)c(Cl)c2C)c2nc(N)nc(Cl)c12 Chemical compound CCc1c[n](Cc2ncc(C)c(Cl)c2C)c2nc(N)nc(Cl)c12 CWDAXYXBEUCCII-UHFFFAOYSA-N 0.000 description 1
- IBZNHZNCSKEWCW-UHFFFAOYSA-N Cc(c(Br)c(C[n]1c2nc(N)nc(Cl)c2c(-c2ccccc2)c1)nc1C)c1O Chemical compound Cc(c(Br)c(C[n]1c2nc(N)nc(Cl)c2c(-c2ccccc2)c1)nc1C)c1O IBZNHZNCSKEWCW-UHFFFAOYSA-N 0.000 description 1
- AMAPWHCRXIPWMV-UHFFFAOYSA-N Cc(cnc(C[n]1c2nc(N)nc(Cl)c2c(-c2ccccc2)c1)c1C)c1OC Chemical compound Cc(cnc(C[n]1c2nc(N)nc(Cl)c2c(-c2ccccc2)c1)c1C)c1OC AMAPWHCRXIPWMV-UHFFFAOYSA-N 0.000 description 1
- LHQRQJCYAGFPFU-UHFFFAOYSA-N Cc1c(C)c(C)c(C[n]2c3nc(N)nc(Cl)c3c(N(C)C)c2)nc1 Chemical compound Cc1c(C)c(C)c(C[n]2c3nc(N)nc(Cl)c3c(N(C)C)c2)nc1 LHQRQJCYAGFPFU-UHFFFAOYSA-N 0.000 description 1
- OMYNIKZBVKBQEG-UHFFFAOYSA-N Cc1c[n](Cc2c(C)c(C)c(C)cn2)c2nc(N)nc(Cl)c12 Chemical compound Cc1c[n](Cc2c(C)c(C)c(C)cn2)c2nc(N)nc(Cl)c12 OMYNIKZBVKBQEG-UHFFFAOYSA-N 0.000 description 1
- OKNZIPMFCKVSGB-UHFFFAOYSA-N Cc1cnc(CN2c3nc(N)nc(Cl)c3CC2=O)c(C)c1OC Chemical compound Cc1cnc(CN2c3nc(N)nc(Cl)c3CC2=O)c(C)c1OC OKNZIPMFCKVSGB-UHFFFAOYSA-N 0.000 description 1
- HQERJIVZQITFAB-UHFFFAOYSA-N Cc1cnc(C[n]2c3nc(N)nc(Br)c3nc2)c(C)c1C Chemical compound Cc1cnc(C[n]2c3nc(N)nc(Br)c3nc2)c(C)c1C HQERJIVZQITFAB-UHFFFAOYSA-N 0.000 description 1
- FAWWCBAWBLXIDK-UHFFFAOYSA-N Cc1cnc(C[n]2c3nc(N)nc(Cl)c3c(-c3ccccc3)c2)c(C)c1Br Chemical compound Cc1cnc(C[n]2c3nc(N)nc(Cl)c3c(-c3ccccc3)c2)c(C)c1Br FAWWCBAWBLXIDK-UHFFFAOYSA-N 0.000 description 1
- FSEJZHJBGPSNLT-UHFFFAOYSA-N Cc1cnc(C[n]2c3nc(N)nc(Cl)c3c(N(C)C)c2)c(C)c1OC Chemical compound Cc1cnc(C[n]2c3nc(N)nc(Cl)c3c(N(C)C)c2)c(C)c1OC FSEJZHJBGPSNLT-UHFFFAOYSA-N 0.000 description 1
- ASKOHPBJRRSUSJ-UHFFFAOYSA-N Nc1nc(Cl)c(cn[nH]2)c2n1 Chemical compound Nc1nc(Cl)c(cn[nH]2)c2n1 ASKOHPBJRRSUSJ-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50413503P | 2003-09-18 | 2003-09-18 | |
US60/504,135 | 2003-09-18 | ||
US59146704P | 2004-07-26 | 2004-07-26 | |
US60/591,467 | 2004-07-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20060070572A true KR20060070572A (ko) | 2006-06-23 |
Family
ID=34381103
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020067007478A KR20060070572A (ko) | 2003-09-18 | 2004-09-20 | Hsp90-저해제로서의 신규 헤테로시클릭 화합물 |
Country Status (14)
Families Citing this family (181)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6992188B1 (en) * | 1995-12-08 | 2006-01-31 | Pfizer, Inc. | Substituted heterocyclic derivatives |
CN101928288B (zh) * | 2000-11-02 | 2013-09-11 | 斯隆-凯特林癌症研究所 | 结合hsp90的小分子组合物 |
AU2002315389A1 (en) * | 2001-06-21 | 2003-01-08 | Ariad Pharmaceuticals, Inc. | Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof |
US20070129334A1 (en) * | 2001-10-30 | 2007-06-07 | Conforma Therapeutics Corporation | Orally Active Purine-Based Inhibitors of Heat Shock Protein 90 |
JP4397691B2 (ja) * | 2001-10-30 | 2010-01-13 | コンフォーマ・セラピューティクス・コーポレイション | Hsp90阻害活性を有するプリン類似体 |
KR20060070572A (ko) * | 2003-09-18 | 2006-06-23 | 콘포마 세러퓨틱스 코포레이션 | Hsp90-저해제로서의 신규 헤테로시클릭 화합물 |
AU2005302000A1 (en) * | 2004-11-02 | 2006-05-11 | Conforma Therapeutics Corporation | Methods and compositions for treating chronic lymphocytic leukemia |
WO2006050373A2 (en) * | 2004-11-02 | 2006-05-11 | The Regents Of The University Of California | Methods and compositions for modulating apoptosis |
US8212012B2 (en) * | 2004-11-03 | 2012-07-03 | University Of Kansas | Novobiocin analogues having modified sugar moieties |
US9120774B2 (en) | 2004-11-03 | 2015-09-01 | University Of Kansas | Novobiocin analogues having modified sugar moieties |
NZ561939A (en) | 2005-03-30 | 2011-03-31 | Conforma Therapeutics Corp | Alkynyl pyrrolopyrimidines and related analogs as HSP90-inhibitors |
PT2332909E (pt) * | 2005-04-13 | 2014-12-17 | Astex Therapeutics Ltd | Derivados de hidroxibenzamida e sua utilização como inibidores de hsp90 |
JP2008536867A (ja) * | 2005-04-14 | 2008-09-11 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド | 増殖疾患を処置する際に有用なhsp90インヒビターとしての2−アミノ−キナゾリン−5−オン |
WO2006124897A2 (en) * | 2005-05-13 | 2006-11-23 | Lexicon Genetics Incorporated | Methods and compositions for improving cognition |
US7932257B2 (en) * | 2005-07-22 | 2011-04-26 | Sunesis Pharmaceuticals, Inc. | Substituted pyrazolo[4,3-d]pyrimidines as aurora kinase inhibitors |
CN101304748A (zh) * | 2005-08-22 | 2008-11-12 | 加利福尼亚大学董事会 | Tlr激动剂 |
EP1926734A1 (en) | 2005-08-22 | 2008-06-04 | Amgen Inc. | Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators |
JP2009506036A (ja) * | 2005-08-24 | 2009-02-12 | レキシコン・ファーマシューティカルズ・インコーポレーテッド | ピロロピリジン、ピロロピリミジンおよびピラゾロピリジン化合物、それらを含む組成物、ならびにそれらの使用方法 |
US20070105874A1 (en) * | 2005-09-23 | 2007-05-10 | Conforma Therapeutics Corporation | Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors |
WO2007058879A2 (en) * | 2005-11-10 | 2007-05-24 | Smithkline Beecham Corporation | Inhibitors of akt activity |
JP2009517342A (ja) * | 2005-11-10 | 2009-04-30 | スミスクライン・ビーチャム・コーポレイション | Akt活性の阻害剤 |
EP1962863A4 (en) * | 2005-12-22 | 2010-11-24 | Conforma Therapeutics Corp | ORALLY ACTIVE PURINE INHIBITORS OF THERMAL SHOCK PROTEIN 90 |
EP2012791A4 (en) * | 2006-02-07 | 2010-09-22 | Conforma Therapeutics Corp | 7,9-DIHYDRO-PURIN-8-ONE AND RELATED ANALOGUES AS INHIBITORS OF HSP90 |
US8658633B2 (en) * | 2006-02-16 | 2014-02-25 | Massachusetts Eye And Ear Infirmary | Methods and compositions for treating conditions of the eye |
EP2038041A4 (en) | 2006-05-12 | 2010-02-17 | Myriad Genetics Inc | THERAPEUTIC COMPOUNDS AND THEIR USE AGAINST CANCER |
EP2700638A1 (en) * | 2006-05-31 | 2014-02-26 | The Regents Of the University of California | Purine analogs |
US10336757B2 (en) * | 2006-06-30 | 2019-07-02 | Sloan-Kettering Institute For Cancer Research | Treatment of neurodegenerative diseases through inhibition of HSP90 |
US20080009508A1 (en) * | 2006-07-10 | 2008-01-10 | Lucie Szucova | 6,9-Disubstituted Purine Derivatives And Their Use For Treating Skin |
DK1887359T3 (da) * | 2006-08-03 | 2009-03-02 | Cellzome Ag | Fremgangsmåde til identifikation af PI3K-interagerende molekyler og til rensning af PI3K |
KR101485199B1 (ko) | 2006-09-19 | 2015-01-22 | 다이이찌 산쿄 가부시키가이샤 | 피라졸로피리미딘 유도체 |
WO2008045529A1 (en) * | 2006-10-12 | 2008-04-17 | Serenex, Inc. | Purine and pyrimidine derivatives for treatment of cancer and inflammatory diseases |
CL2007002994A1 (es) * | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
FR2907453B1 (fr) * | 2006-10-24 | 2008-12-26 | Sanofi Aventis Sa | Nouveaux derives du fluorene,compositions les contenant et utilisation |
GB0622084D0 (en) * | 2006-11-06 | 2006-12-13 | Chroma Therapeutics Ltd | Inhibitors of HSP90 |
CA2676658A1 (en) * | 2007-01-30 | 2008-08-07 | Biogen Idec Ma Inc. | Modulators of mitotic kinases |
RU2009132605A (ru) * | 2007-02-01 | 2011-03-10 | Астразенека Аб (Se) | Производные 5,6,7,8-тетрагидроптеридина в качестве ингибиторов hsp90 |
ES2456964T3 (es) | 2007-02-07 | 2014-04-24 | The Regents Of The University Of California | Conjugados de agonistas de TLR sintéticos y usos de los mismos |
KR101313804B1 (ko) * | 2007-03-20 | 2013-10-01 | 쿠리스 인코퍼레이션 | Hsp90 억제제로서의 융합된 아미노 피리딘 |
MX2009010667A (es) | 2007-04-12 | 2010-02-24 | Joyant Pharmaceuticals Inc | Dimeros y trimeros mimeticos de smac utiles como agentes anti-cancer. |
US8143265B2 (en) * | 2007-04-16 | 2012-03-27 | Meharry Medical College | Method of treating atherosclerosis |
US7960353B2 (en) * | 2007-05-10 | 2011-06-14 | University Of Kansas | Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders |
DE102007028521A1 (de) * | 2007-06-21 | 2008-12-24 | Merck Patent Gmbh | Indazolamidderivate |
EP2200653A2 (en) | 2007-09-10 | 2010-06-30 | University of Massachusetts | Mitochondria-targeted anti-tumour agents |
US8119616B2 (en) * | 2007-09-10 | 2012-02-21 | Curis, Inc. | Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety |
US20110160232A1 (en) | 2007-10-04 | 2011-06-30 | Pingda Ren | Certain chemical entities and therapeutic uses thereof |
US7960420B2 (en) | 2007-12-21 | 2011-06-14 | Joyant Pharmaceuticals, Inc | Diazonamide analogs with improved solubility |
US8895701B2 (en) * | 2008-01-05 | 2014-11-25 | Sloan-Kettering Institute For Cancer Research | Peptide-conjugated oligonucleotide therapeutic and method of making and using same |
EA201001264A1 (ru) * | 2008-02-07 | 2011-04-29 | Дзе Регентс Оф Дзе Юниверсити Оф Калифорния | Способ лечения заболеваний мочевого пузыря с помощью активатора tlr7 |
US8190543B2 (en) * | 2008-03-08 | 2012-05-29 | Tokyo Electron Limited | Autonomous biologically based learning tool |
WO2009114470A2 (en) * | 2008-03-10 | 2009-09-17 | Curis, Inc. | Tetrahydroindole and tetrahdyroindazole as hsp90 inhibitors containing a zinc binding moiety |
WO2009114874A2 (en) * | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Benzothiazole kinase inhibitors and methods of use |
US8637542B2 (en) | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
JP5123429B2 (ja) | 2008-04-29 | 2013-01-23 | ジョイアント ファーマスーティカルズ、インク. | インドリン抗癌剤 |
LT5623B (lt) | 2008-04-30 | 2010-01-25 | Biotechnologijos Institutas, , | 5-aril-4-(5-pakeistieji 2,4-dihidroksifenil)-1,2,3-tiadiazolai kaip hsp90 šaperono slopikliai ir tarpiniai junginiai jiems gauti |
EP2273882A4 (en) * | 2008-05-13 | 2011-07-13 | Poniard Pharmaceuticals Inc | BIOACTIVE COMPOUNDS FOR THE TREATMENT OF CANCER AND NEURODEEGENERATIVE DISEASES |
US8153619B2 (en) | 2008-05-22 | 2012-04-10 | Joyant Pharmaceuticals, Inc. | Diazonamide analogs |
BRPI0915231A2 (pt) | 2008-07-08 | 2018-06-12 | Intellikine Inc | compostos inibidores de quinase e métodos de uso |
US20100022635A1 (en) * | 2008-07-28 | 2010-01-28 | University Of Kansas | Heat shock protein 90 inhibitor dosing methods |
GB0819102D0 (en) * | 2008-10-17 | 2008-11-26 | Chroma Therapeutics Ltd | Pyrrolo-pyrimidine compounds |
US8476282B2 (en) | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
EP2373317B1 (en) * | 2008-11-25 | 2016-12-14 | Merck Sharp & Dohme Corp. | 4-amino-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one or 4-amino-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one derivatives as activators of the soluble guanylat cyclase for the treatment of cardiovascular diseases |
MX2011007612A (es) | 2009-01-16 | 2012-01-20 | Curis Inc | Aminopiridinas fusionadas para el tratamiento de tumores del cerebro. |
WO2010088924A1 (en) | 2009-02-06 | 2010-08-12 | Telormedix Sa | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
SG173617A1 (en) * | 2009-02-11 | 2011-09-29 | Univ California | Toll-like receptor modulators and treatment of diseases |
MX2011008677A (es) | 2009-02-25 | 2011-09-08 | Daiichi Sankyo Co Ltd | Derivados de pirazolopirimidina triciclicos. |
DK2770327T3 (en) * | 2009-03-30 | 2017-08-28 | Nordic Bioscience As | BIOMARKERING ASSAY FOR FIBROSE |
WO2010117425A1 (en) * | 2009-03-31 | 2010-10-14 | Biogen Idec Ma Inc. | Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use |
JP5677425B2 (ja) | 2009-06-29 | 2015-02-25 | インサイト・コーポレイションIncyte Corporation | Pi3k阻害剤としてのピリミジノン |
WO2011004610A1 (ja) * | 2009-07-10 | 2011-01-13 | 大鵬薬品工業株式会社 | アザ二環式化合物又はその塩 |
MX2012002066A (es) | 2009-08-17 | 2012-03-29 | Intellikine Inc | Compuestos heterociclicos y usos de los mismos. |
US20110082098A1 (en) * | 2009-09-30 | 2011-04-07 | University Of Kansas | Novobiocin analogues and treatment of polycystic kidney disease |
NZ599138A (en) | 2009-10-07 | 2014-06-27 | Sloan Kettering Inst Cancer | Purine derivatives useful as hsp90 inhibitors |
EP2784076A1 (en) | 2009-10-28 | 2014-10-01 | Joyant Pharmaceuticals, Inc. | Dimeric SMAC mimetics |
US20110130711A1 (en) * | 2009-11-19 | 2011-06-02 | Follica, Inc. | Hair growth treatment |
WO2011075643A1 (en) * | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted heteroaryl fused derivatives as pi3k inhibitors |
US8680108B2 (en) * | 2009-12-18 | 2014-03-25 | Incyte Corporation | Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors |
AR079545A1 (es) | 2009-12-21 | 2012-02-01 | Bayer Cropscience Ag | Tienilpiri(mi)dinilazol |
CA2796311A1 (en) | 2010-04-14 | 2011-10-20 | Incyte Corporation | Fused derivatives as pi3k.delta. inhibitors |
AU2011247358B2 (en) | 2010-04-30 | 2014-10-30 | Urogen Pharma Ltd. | Phospholipid drug analogs |
US9050319B2 (en) | 2010-04-30 | 2015-06-09 | Telormedix, Sa | Phospholipid drug analogs |
WO2011146313A1 (en) * | 2010-05-19 | 2011-11-24 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
WO2011163195A1 (en) | 2010-06-21 | 2011-12-29 | Incyte Corporation | Fused pyrrole derivatives as pi3k inhibitors |
JPWO2012026433A1 (ja) | 2010-08-23 | 2013-10-28 | 第一三共株式会社 | 三環性ピラゾロピリミジン誘導体のフリー体結晶 |
TW201213333A (en) | 2010-08-23 | 2012-04-01 | Daiichi Sankyo Co Ltd | Crystal forms of tricyclic pyrazolopyrimidine derivative |
WO2012064744A2 (en) | 2010-11-08 | 2012-05-18 | Lycera Corporation | Tetrahydroquinoline and related bicyclic compounds for inhibition of rorϒ activity and the treatment of disease |
WO2012083181A1 (en) * | 2010-12-16 | 2012-06-21 | Indiana University Research And Technology Corporation | Alpha helix mimetics and methods for using |
NZ609448A (en) | 2010-12-16 | 2015-07-31 | Hoffmann La Roche | Tricyclic pi3k inhibitor compounds and methods of use |
EP2655374B1 (en) | 2010-12-20 | 2019-10-23 | Incyte Holdings Corporation | N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors |
US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
US8362023B2 (en) | 2011-01-19 | 2013-01-29 | Hoffmann-La Roche Inc. | Pyrazolo pyrimidines |
JP5766820B2 (ja) * | 2011-02-09 | 2015-08-19 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Pi3キナーゼ阻害剤としての複素環化合物 |
US9295673B2 (en) | 2011-02-23 | 2016-03-29 | Intellikine Llc | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof |
WO2012125629A1 (en) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors |
US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
AU2012240079B2 (en) | 2011-04-05 | 2017-05-18 | Sloan-Kettering Institute For Cancer Research | Hsp90 inhibitors |
CN103582642B (zh) | 2011-04-05 | 2021-05-11 | 索隆-基特林癌症研究协会 | Hsp90抑制剂 |
WO2012145255A2 (en) | 2011-04-22 | 2012-10-26 | Joyant Pharmaceuticals, Inc. | Diazonamide analogs |
JP2014515368A (ja) | 2011-05-26 | 2014-06-30 | 第一三共株式会社 | プロテインキナーゼ阻害剤としての複素環化合物 |
WO2012178125A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
ITTO20110652A1 (it) * | 2011-07-20 | 2013-01-21 | Medestea Res & Production S P A | Composto derivato dall'adenina avente azione immuno-modulante, antinfiammatoria e antidolorifica |
KR102507287B1 (ko) | 2011-09-02 | 2023-03-07 | 인사이트 홀딩스 코포레이션 | Pi3k 억제제로서 헤테로시클릴아민 |
CA2850617A1 (en) | 2011-10-03 | 2013-04-11 | The University Of North Carolina At Chapel Hill | Pyrrolopyrimidine compounds for the treatment of cancer |
AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
US9394315B2 (en) | 2012-05-08 | 2016-07-19 | Lycera Corporation | Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
US9657033B2 (en) | 2012-05-08 | 2017-05-23 | Lycera Corporation | Tetrahydronaphthyridine and related bicyclic compounds for inhibition of RORγ activity and the treatment of disease |
WO2013172872A1 (en) * | 2012-05-15 | 2013-11-21 | Calasia Pharmaceuticals, Inc. | Pyrimidine diamine derivatives as inhibitors of cytosolic hsp90 |
WO2013177168A1 (en) | 2012-05-22 | 2013-11-28 | The University Of North Carolina At Chapel Hill | Pyrimidine compounds for the treatment of cancer |
ME03300B (me) | 2012-06-13 | 2019-07-20 | Incyte Holdings Corp | Supsтituisana triciklična jedinjenja као inhibiтori fgfr |
WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
EP2904119B1 (en) | 2012-10-02 | 2020-06-17 | The General Hospital Corporation d/b/a Massachusetts General Hospital | Methods relating to dna-sensing pathway related conditions |
JP2015531395A (ja) | 2012-10-04 | 2015-11-02 | ファイザー・リミテッドPfizer Limited | ピロロ[3,2−c]ピリジントロポミオシン関連キナーゼ阻害剤 |
CN103724269B (zh) * | 2012-10-11 | 2016-12-21 | 中国科学院上海药物研究所 | 苯基1,2-异噁唑或苯基1,2-吡唑类化合物及其用途 |
WO2014062774A1 (en) | 2012-10-17 | 2014-04-24 | The University Of North Carolina At Chapel Hill | Pyrazolopyrimidine compounds for the treatment of cancer |
EP2925752A4 (en) | 2012-11-27 | 2016-06-01 | Univ North Carolina | PYRIMIDINE COMPOUNDS FOR CANCER TREATMENT |
PL3808749T3 (pl) | 2012-12-07 | 2023-07-10 | Vertex Pharmaceuticals Incorporated | Pirazolo[1,5-a]pirymidyny użyteczne jako inhibitory kinazy atr do leczenia chorób nowotworowych |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
WO2014143240A1 (en) | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
EP2970288A1 (en) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
AU2014228822A1 (en) | 2013-03-15 | 2015-10-01 | Memorial Sloan-Kettering Cancer Center | HSP90-targeted cardiac imaging and therapy |
WO2014145576A2 (en) * | 2013-03-15 | 2014-09-18 | Northwestern University | Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer |
EP2970289A1 (en) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
WO2014153509A1 (en) | 2013-03-22 | 2014-09-25 | Millennium Pharmaceuticals, Inc. | Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase |
DK2986610T5 (en) | 2013-04-19 | 2018-12-10 | Incyte Holdings Corp | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS |
CN112472699A (zh) | 2013-07-26 | 2021-03-12 | 种族肿瘤学公司 | 改善比生群及衍生物的治疗益处的组合方法 |
AU2014306417C1 (en) | 2013-08-16 | 2019-07-25 | Memorial Sloan-Kettering Cancer Center | Selective Grp94 inhibitors and uses thereof |
JP6543252B2 (ja) | 2013-12-06 | 2019-07-10 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | ATRキナーゼ阻害剤として有用な2−アミノ−6−フルオロ−N−[5−フルオロ−ピリジン−3−イル]ピラゾロ[1,5−a]ピリミジン−3−カルボキサミド化合物、その調製、その異なる固体形態および放射性標識された誘導体 |
US9663502B2 (en) | 2013-12-20 | 2017-05-30 | Lycera Corporation | 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease |
US9783511B2 (en) | 2013-12-20 | 2017-10-10 | Lycera Corporation | Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease |
US9809561B2 (en) | 2013-12-20 | 2017-11-07 | Merck Sharp & Dohme Corp. | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease |
CN106132422A (zh) | 2014-02-27 | 2016-11-16 | 莱斯拉公司 | 使用视黄酸受体相关孤儿受体γ的激动剂的过继细胞疗法&相关治疗方法 |
ES2548927B1 (es) * | 2014-03-21 | 2016-08-11 | Universidad De Granada | Derivados de purina como inhibidores de Dapk-1 |
WO2015157125A1 (en) | 2014-04-11 | 2015-10-15 | The University Of North Carolina At Chapel Hill | Therapuetic uses of selected pyrazolopyrimidine compounds with anti-mer tyrosine kinase activity |
AU2015256190B2 (en) | 2014-05-05 | 2019-08-15 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease |
EP3209641A4 (en) | 2014-05-05 | 2018-06-06 | Lycera Corporation | Benzenesulfonamido and related compounds for use as agonists of ror and the treatement of disease |
MX2016015874A (es) | 2014-06-05 | 2017-03-27 | Vertex Pharma | Derivados radiomarcadores de un compuesto de 2-amino-6-fluoro-n-[5 -fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida util como inhibidor de ataxia telangiectasia mutada y rad3 relacionado (atr) cinasa, preparacion de tal compuesto y diferentes formas solidas del mismo. |
US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
PT3157566T (pt) | 2014-06-17 | 2019-07-11 | Vertex Pharma | Método para tratamento de cancro utilizando uma combinação de inibidores chk1 e atr |
CA2961499A1 (en) | 2014-09-17 | 2016-03-24 | Memorial Sloan Kettering Cancer Center | Hsp90-targeted inflammation and infection imaging and therapy |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
KR101713638B1 (ko) * | 2014-11-18 | 2017-03-08 | 한국과학기술연구원 | 신규한 피롤로 피리미딘 유도체 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
JP2018510135A (ja) | 2015-02-11 | 2018-04-12 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | RORγT阻害剤としての置換ピラゾール化合物及びその使用 |
EA038045B1 (ru) | 2015-02-20 | 2021-06-28 | Инсайт Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
PE20180129A1 (es) | 2015-02-27 | 2018-01-18 | Incyte Corp | Sales de inhibidor de pi3k y procesos de preparacion |
CA2982847A1 (en) | 2015-05-05 | 2016-11-10 | Lycera Corporation | Dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease |
US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
KR20180025894A (ko) | 2015-06-11 | 2018-03-09 | 라이세라 코퍼레이션 | Rory의 작용제로서 사용하기 위한 아릴 디히드로-2h-벤조[b][1,4]옥사진 술폰아미드 및 관련 화합물 및 질환의 치료 |
CA3217238A1 (en) * | 2015-07-20 | 2017-01-26 | Genzyme Corporation | Colony stimulating factor-1 receptor (csf-1r) inhibitors |
CA3000684A1 (en) | 2015-09-30 | 2017-04-06 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of dna damaging agents and atr inhibitors |
EP3368539B1 (en) | 2015-10-27 | 2020-12-02 | Merck Sharp & Dohme Corp. | Substituted indazole compounds as ror gamma t inhibitors and uses thereof |
WO2017075178A1 (en) | 2015-10-27 | 2017-05-04 | Merck Sharp & Dohme Corp. | SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
EP3368535B1 (en) | 2015-10-27 | 2020-12-02 | Merck Sharp & Dohme Corp. | Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof |
US10709708B2 (en) | 2016-03-17 | 2020-07-14 | The University Of North Carolina At Chapel Hill | Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor |
US11697851B2 (en) | 2016-05-24 | 2023-07-11 | The Regents Of The University Of California | Early ovarian cancer detection diagnostic test based on mRNA isoforms |
KR101896616B1 (ko) * | 2016-10-11 | 2018-09-07 | 한국과학기술연구원 | 2-아미노 퓨린 유도체 화합물, 이를 제조하는 방법, 및 이의 용도 |
WO2018079988A1 (ko) * | 2016-10-26 | 2018-05-03 | 울산과학기술원 | Trap1 저해제로서 유용한 화합물 및 이를 포함하는 항암용 조성물 |
CN109311897B (zh) | 2017-03-20 | 2021-07-20 | 福马治疗股份有限公司 | 作为丙酮酸激酶(pkr)活化剂的吡咯并吡咯组合物 |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
US10472361B2 (en) | 2017-08-16 | 2019-11-12 | Bristol-Myers Squibb Company | Toll-like receptor 7 (TLR7) agonists having a benzotriazole moiety, conjugates thereof, and methods and uses therefor |
JOP20180094A1 (ar) | 2017-10-18 | 2019-04-18 | Hk Inno N Corp | مركب حلقي غير متجانس كمثبط بروتين كيناز |
CN107857763A (zh) * | 2017-11-28 | 2018-03-30 | 江苏杏睿生物科技有限公司 | 一种邻硝基芳酰化衍生物类化合物、制备方法及其应用 |
FR3075794A1 (fr) * | 2017-12-21 | 2019-06-28 | Galderma Research & Development | Nouveaux composes inhibiteurs de mtor |
FR3075795A1 (fr) | 2017-12-21 | 2019-06-28 | Galderma Research & Development | Nouveaux composes inhibiteurs de mtor |
IL276802B2 (en) | 2018-03-09 | 2023-09-01 | Recurium Ip Holdings Llc | Transduced 2,1-dihydro-3h-pyrazolo[4,3-d]pyrimidine-3-ones |
US11466004B2 (en) | 2018-05-04 | 2022-10-11 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
EA202092649A1 (ru) | 2018-05-04 | 2021-06-21 | Инсайт Корпорейшн | Соли ингибитора fgfr |
US20200129485A1 (en) | 2018-09-19 | 2020-04-30 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
US20230055923A1 (en) | 2018-09-19 | 2023-02-23 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
IL291901A (en) | 2019-10-14 | 2022-06-01 | Incyte Corp | Bicyclyl heterocycles as fgr suppressors |
WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
KR20220131900A (ko) | 2019-12-04 | 2022-09-29 | 인사이트 코포레이션 | Fgfr 억제제의 유도체 |
WO2021113479A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
KR102516260B1 (ko) * | 2020-07-10 | 2023-03-31 | 울산과학기술원 | Trap1 선택적 억제제로서의 화합물 및 이를 포함하는 암 예방 또는 치료용 조성물 |
JP2024500919A (ja) | 2020-12-23 | 2024-01-10 | ジェンザイム・コーポレーション | 重水素化コロニー刺激因子-1受容体(csf-1r)阻害剤 |
AR126102A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
CN115925724A (zh) * | 2022-11-16 | 2023-04-07 | 成都中医药大学 | 一种具有抗炎作用的腺嘌呤类化合物及其制备方法与应用 |
CN116332940A (zh) * | 2023-02-14 | 2023-06-27 | 广西民族大学 | 一种7-脱氮嘌呤衍生物及其制备方法和应用 |
Family Cites Families (119)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB884151A (en) | 1957-12-06 | 1961-12-06 | Ciba Ltd | New pyrazolo-pyrimidines substituted in the pyrazole nucleus, and process for their manufacture |
IL64501A (en) | 1980-12-22 | 1985-07-31 | Astra Laekemedel Ab | 9-substituted 4-hydroxybutyl guanine derivatives,their preparation and antiviral use |
US4699877A (en) | 1982-11-04 | 1987-10-13 | The Regents Of The University Of California | Methods and compositions for detecting human tumors |
US4921859A (en) | 1983-10-31 | 1990-05-01 | Warner-Lambert Company | Purine derivatives |
US5098906A (en) | 1983-10-31 | 1992-03-24 | Warner-Lambert Company | Purine derivatives |
US4806642A (en) | 1984-10-05 | 1989-02-21 | Warner-Lambert Company | Purine derivatives |
US4547573A (en) | 1983-12-02 | 1985-10-15 | Ici Pharma | Process for preparing cephalosporin derivatives |
EP0151528B1 (en) | 1984-02-02 | 1990-07-04 | Merck & Co. Inc. | 5-(amino or substituted amino)-1,2,3-triazoles |
US4748177A (en) | 1984-03-26 | 1988-05-31 | Warner-Lambert Company | Guanine derivatives |
US4617304A (en) | 1984-04-10 | 1986-10-14 | Merck & Co., Inc. | Purine derivatives |
IT1196261B (it) * | 1984-09-20 | 1988-11-16 | Pierrel Spa | Derivati nucleosidici e purinici 8-sostituiti |
ZA857647B (en) * | 1984-10-12 | 1986-05-28 | Warner Lambert Co | Purine derivatives |
US4772606A (en) * | 1985-08-22 | 1988-09-20 | Warner-Lambert Company | Purine derivatives |
IL76546A (en) | 1984-10-12 | 1988-12-30 | Warner Lambert Co | 9-(heteroarylalkyl)-6-purine(thi)one derivatives,their preparation and pharmaceutical compositions containing them |
JO1406B1 (en) | 1984-11-02 | 1986-11-30 | سميث كلاين اند فرينش لابوراتوريز ليمتد | Chemical compounds |
US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
DE3650699T2 (de) | 1985-03-15 | 1999-04-15 | Antivirals Inc | Immunotestmittel für Polynukleotid und Verfahren |
IL78643A0 (en) | 1985-05-02 | 1986-08-31 | Wellcome Found | Purine derivatives,their preparation and pharmaceutical compositions containing them |
GB8515934D0 (en) | 1985-06-24 | 1985-07-24 | Janssen Pharmaceutica Nv | (4-piperidinomethyl and-hetero)purines |
US4918162A (en) | 1986-05-06 | 1990-04-17 | The Regents Of The University Of California | Assays and antibodies for N-MYC proteins |
DE3623099C3 (de) * | 1986-07-09 | 1998-08-13 | Spoetzl Markus Dipl Ing Fh | Blasformmaschine |
US5002950A (en) * | 1986-10-24 | 1991-03-26 | Warner-Lambert Co. | 7-deazaguanines as immunomodulators |
US4968603A (en) * | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
US5204353A (en) | 1987-04-07 | 1993-04-20 | Ciba-Geigy Corporation | 3-benzyl-3H-1,2,3-triazolo[4,5-d]pyrimidines, compositions thereof, and method of treating epilepsy therewith |
JPH0821101B2 (ja) | 1987-07-21 | 1996-03-04 | 三洋電機株式会社 | 硬貨選別装置 |
SE8801729D0 (sv) | 1988-05-06 | 1988-05-06 | Astra Ab | Purine derivatives for use in therapy |
US4923885A (en) * | 1988-08-19 | 1990-05-08 | Merck & Co., Inc. | 5-amino-1-(4-naphthoylbenzyl)-1,2,3-triazole-4-carboxamides and analogs as antiproliferative agents |
EP0363320A3 (de) | 1988-10-06 | 1991-11-21 | Ciba-Geigy Ag | Substituierte 9H-Purine |
US5332744A (en) | 1989-05-30 | 1994-07-26 | Merck & Co., Inc. | Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists |
DE69116750T2 (de) | 1990-07-04 | 1996-11-14 | Merrell Dow Pharma | 9-Purinyl-Phosphonsäurederivate |
GB9020931D0 (en) | 1990-09-26 | 1990-11-07 | Wellcome Found | Heterocyclic compounds |
DE69230349T2 (de) | 1991-03-05 | 2000-07-27 | Ajinomoto Kk | Cyclopropanderivat |
US5939420A (en) | 1991-04-08 | 1999-08-17 | Duquesne University Of The Holy Ghost | Pyrrolo 2,3d!derivatives |
WO1992021032A1 (en) * | 1991-05-24 | 1992-11-26 | The Regents Of The University Of California | Methods for the detection of bcr-abl and abnormal abl proteins in leukemia patients |
US6025126A (en) * | 1991-10-28 | 2000-02-15 | Arch Development Corporation | Methods and compositions for the detection of chromosomal aberrations |
CA2093403C (en) | 1992-04-08 | 1999-08-10 | Fumio Suzuki | Therapeutic agent for parkinson's disease |
JPH0680670A (ja) | 1992-09-03 | 1994-03-22 | Ajinomoto Co Inc | シクロプロパン誘導体及びその製造法 |
US6005107A (en) | 1992-12-23 | 1999-12-21 | Biochem Pharma, Inc. | Antiviral compounds |
GB9226879D0 (en) * | 1992-12-23 | 1993-02-17 | Iaf Biochem Int | Anti-viral compounds |
US6444656B1 (en) * | 1992-12-23 | 2002-09-03 | Biochem Pharma, Inc. | Antiviral phosphonate nucleotides |
US5744492A (en) | 1993-09-17 | 1998-04-28 | United States Of America | Method for inhibiting angiogenesis |
US5602156A (en) * | 1993-09-17 | 1997-02-11 | The United States Of America As Represented By The Department Of Health And Human Services | Method for inhibiting metalloproteinase expression |
GB9402161D0 (en) * | 1994-02-04 | 1994-03-30 | Wellcome Found | Chloropyrimidine intermediates |
JP3769737B2 (ja) | 1994-03-30 | 2006-04-26 | 味の素株式会社 | シクロプロパン誘導体及びその製造法 |
US5932566A (en) * | 1994-06-16 | 1999-08-03 | Pfizer Inc. | Ansamycin derivatives as antioncogene and anticancer agents |
US5994361A (en) | 1994-06-22 | 1999-11-30 | Biochem Pharma | Substituted purinyl derivatives with immunomodulating activity |
US5525606A (en) | 1994-08-01 | 1996-06-11 | The United States Of America As Represented By The Department Of Health And Human Services | Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines |
JPH0841035A (ja) | 1994-08-05 | 1996-02-13 | Ajinomoto Co Inc | シクロプロパン誘導体及びその製造法 |
US5846749A (en) | 1994-10-12 | 1998-12-08 | The Regents Of The University Of California | Quantitative measurement of tissue protein identified by immunohistochemistry and standardized protein determination |
JPH08208687A (ja) | 1994-11-25 | 1996-08-13 | Sankyo Co Ltd | グリセリルオリゴヌクレオチド |
US5656629A (en) * | 1995-03-10 | 1997-08-12 | Sanofi Winthrop, Inc. | 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof |
US6177460B1 (en) * | 1995-04-12 | 2001-01-23 | The Procter & Gamble Company | Method of treatment for cancer or viral infections |
JPH0920776A (ja) | 1995-06-30 | 1997-01-21 | Nippon Paper Ind Co Ltd | 新規なプリンヌクレオシド誘導体、その製造方法及びその誘導体を有効成分とする抗ウイルス剤 |
JPH09169758A (ja) | 1995-10-18 | 1997-06-30 | Nippon Paper Ind Co Ltd | 新規なプリンヌクレオシド誘導体、その製造方法、及びそれを用いた抗ウイルス剤 |
JPH1025294A (ja) * | 1996-03-26 | 1998-01-27 | Akira Matsuda | 縮合ヘテロ環誘導体、その製造法及びそれを含有する悪性腫瘍治療剤 |
AU698419B2 (en) | 1996-07-03 | 1998-10-29 | Dainippon Sumitomo Pharma Co., Ltd. | A novel purine derivative |
US6723727B1 (en) * | 1996-12-20 | 2004-04-20 | Hoechst Aktiengesellschaft | Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them |
WO1998039344A1 (en) | 1997-03-07 | 1998-09-11 | Metabasis Therapeutics, Inc. | Novel purine inhibitors of fructose-1,6-bisphosphatase |
US5861503A (en) * | 1997-04-30 | 1999-01-19 | The Regents Of The University Of California | Process for producing 8-fluoropurines |
JP4903922B2 (ja) | 1997-05-14 | 2012-03-28 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | 選択された蛋白質を分解する複合化合物 |
CN1268137A (zh) | 1997-07-03 | 2000-09-27 | 杜邦药品公司 | 治疗神经失调的咪唑并嘧啶和咪唑并吡啶 |
EP1017394B1 (en) | 1997-07-12 | 2005-12-07 | Cancer Research Technology Limited | Cyclin dependent kinase inhibiting purine derivatives |
GB9717849D0 (en) | 1997-08-23 | 1997-10-29 | Seal Sands Chemicals Limited | Preparation of pyridene derivatives |
AUPO912997A0 (en) | 1997-09-11 | 1997-10-02 | Commonwealth Scientific And Industrial Research Organisation | Antiviral agents |
US5968921A (en) * | 1997-10-24 | 1999-10-19 | Orgegon Health Sciences University | Compositions and methods for promoting nerve regeneration |
DE69824632T2 (de) | 1997-11-12 | 2005-06-09 | Mitsubishi Chemical Corp. | Purinderivate und medikamente, welche dieselben als aktiven bestandteil enthalten |
TW572758B (en) | 1997-12-22 | 2004-01-21 | Sumitomo Pharma | Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives |
WO1999051223A1 (en) | 1998-04-03 | 1999-10-14 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke |
US5985060A (en) | 1998-07-25 | 1999-11-16 | Breed Automotive Technology, Inc. | Gas generant compositions containing guanidines |
SI20022A (sl) | 1998-07-29 | 2000-02-29 | Kemijski inštitut | Alkilno substituirani purinovi derivati in njihova priprava |
JP2000072773A (ja) | 1998-08-28 | 2000-03-07 | Zeria Pharmaceut Co Ltd | プリン誘導体 |
US6369092B1 (en) * | 1998-11-23 | 2002-04-09 | Cell Pathways, Inc. | Method for treating neoplasia by exposure to substituted benzimidazole derivatives |
JP2002539076A (ja) * | 1999-01-06 | 2002-11-19 | ユニバーシティ・オブ・サザン・カリフォルニア | 新脈管形成抑制のための方法および組成物 |
CZ27399A3 (cs) | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
DK1150982T3 (da) | 1999-02-01 | 2005-12-27 | Cv Therapeutics Inc | Purininhibitorer af cylkineafhængig kinase 2 og 1kB-alfa |
FR2790702B1 (fr) | 1999-03-08 | 2001-07-20 | Sidel Sa | Unite de moulage et machine d'extrusion-soufflage munie d'une telle unite |
US6174875B1 (en) * | 1999-04-01 | 2001-01-16 | University Of Pittsburgh | Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke |
WO2000068230A1 (en) | 1999-05-05 | 2000-11-16 | Darwin Discovery Limited | 9-(1,2,3,4-tetrahydronaphthalen-1-yl)-1,9-dihydropurin-6-one derivatives as pde7 inhibitors |
US6660845B1 (en) * | 1999-11-23 | 2003-12-09 | Epoch Biosciences, Inc. | Non-aggregating, non-quenching oligomers comprising nucleotide analogues; methods of synthesis and use thereof |
AU2728201A (en) | 1999-12-21 | 2001-07-03 | Sugen, Inc. | 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors |
US20030187261A1 (en) | 2000-01-07 | 2003-10-02 | Libor Havlicek | Purine derivatives, process for their preparation and use thereof |
AU2001247759A1 (en) | 2000-03-24 | 2001-10-08 | Duke University | Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto |
WO2001081346A2 (en) | 2000-04-25 | 2001-11-01 | Icos Corporation | Inhibitors of human phosphatidyl-inositol 3-kinase delta |
US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
US6887853B2 (en) | 2000-06-29 | 2005-05-03 | The Trustees Of Boston University | Use of geldanamycin and related compounds for treatment of fibrogenic disorders |
US6946456B2 (en) | 2000-07-28 | 2005-09-20 | Sloan-Kettering Institute For Cancer Research | Methods for treating cell proliferative disorders and viral infections |
US6613089B1 (en) | 2000-10-25 | 2003-09-02 | Sdgi Holdings, Inc. | Laterally expanding intervertebral fusion device |
WO2002036171A1 (en) | 2000-11-02 | 2002-05-10 | Sloan Kettering Institute For Cancer Research | Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors |
CN101928288B (zh) * | 2000-11-02 | 2013-09-11 | 斯隆-凯特林癌症研究所 | 结合hsp90的小分子组合物 |
GB0100623D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds IV |
GB0100621D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds VI |
GB0100624D0 (en) * | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds VII |
MY141789A (en) * | 2001-01-19 | 2010-06-30 | Lg Chem Investment Ltd | Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same. |
EP1423080A4 (en) | 2001-03-01 | 2009-06-03 | Conforma Therapeutics Corp | PROCESS FOR TREATING PROLIFERATIVE GENETIC DISORDERS WITH HSP90 INHIBITORS |
CA2377054C (en) * | 2001-03-16 | 2006-09-05 | Susan M. Boyetchko | Biocontrol of weeds using pseudomonas compositions |
JP4331944B2 (ja) | 2001-04-17 | 2009-09-16 | 大日本住友製薬株式会社 | 新規アデニン誘導体 |
US20020156277A1 (en) * | 2001-04-20 | 2002-10-24 | Fick David B. | Synthesis and methods of use of purine analogues and derivatives |
US20030022864A1 (en) | 2001-04-24 | 2003-01-30 | Ishaq Khalid S. | 9-[(5-dihydroxyboryl)-pentyl] purines, useful as an inhibitor of inflammatory cytokines |
WO2002088079A2 (en) | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
WO2002094196A2 (en) | 2001-05-23 | 2002-11-28 | Sloan Kettering Institute For Cancer Research | Method of treatment for cancers associated with elevated |
PE20030008A1 (es) | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
US6949522B2 (en) | 2001-06-22 | 2005-09-27 | Pharmasset, Inc. | β-2′- or 3′-halonucleosides |
DE60205376T2 (de) | 2001-06-27 | 2006-04-06 | Cyclacel Ltd. | 2,6,9-substituierte purinderivate und ihre verwendung bei der behandlung proliferativer krankheiten |
US6962991B2 (en) | 2001-09-12 | 2005-11-08 | Epoch Biosciences, Inc. | Process for the synthesis of pyrazolopyrimidines |
DE60225307T2 (de) | 2001-09-24 | 2009-03-19 | Conforma Therapeutics Corp., San Diego | Verfahren zur herstellung von 17-allyl-amino-geldanamycin (17-aag) und anderer ansamycine |
DE60230818D1 (de) | 2001-09-24 | 2009-02-26 | Imp Innovations Ltd | Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit |
JP2003113181A (ja) | 2001-10-04 | 2003-04-18 | Sumika Fine Chemicals Co Ltd | 6−ハロプリンの製造方法 |
JP4397691B2 (ja) | 2001-10-30 | 2010-01-13 | コンフォーマ・セラピューティクス・コーポレイション | Hsp90阻害活性を有するプリン類似体 |
EP1450784A4 (en) | 2001-11-09 | 2005-02-09 | Conforma Therapeutics Corp | HSP90-INHIBITABLE ZEARALANOL COMPOUNDS AND METHOD FOR THEIR PREPARATION AND USE |
GB0219746D0 (en) * | 2002-08-23 | 2002-10-02 | Inst Of Ex Botany Ascr | Azapurine derivatives |
AU2003267145A1 (en) * | 2002-09-13 | 2004-04-30 | Irm, Llc | Highly specific modulators of gtpases for target validation |
US7601694B2 (en) * | 2003-02-20 | 2009-10-13 | New York University | CLK-peptide and SLK-peptide |
US7560458B2 (en) * | 2003-07-16 | 2009-07-14 | Janssen Pharmaceutica, N.V. | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors |
CA2531232A1 (en) * | 2003-07-16 | 2005-02-10 | Janssen Pharmaceutica N.V. | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors |
WO2005016348A1 (en) | 2003-08-14 | 2005-02-24 | Icos Corporation | Method of inhibiting immune responses stimulated by an endogenous factor |
KR20060070572A (ko) | 2003-09-18 | 2006-06-23 | 콘포마 세러퓨틱스 코포레이션 | Hsp90-저해제로서의 신규 헤테로시클릭 화합물 |
US20080081817A1 (en) * | 2004-07-23 | 2008-04-03 | Tanabe Seiyaku Co., Ltd. | Nitrogenous Fused Bicyclic Compound |
US20070105874A1 (en) * | 2005-09-23 | 2007-05-10 | Conforma Therapeutics Corporation | Anti-Tumor Methods Using Multi Drug Resistance Independent Synthetic HSP90 Inhibitors |
WO2016146042A1 (en) | 2015-03-13 | 2016-09-22 | Acro Biotech Co., Ltd. | Zinc binding fusion protein of glutathione s-transferase and metallothionein |
-
2004
- 2004-09-20 KR KR1020067007478A patent/KR20060070572A/ko not_active Application Discontinuation
- 2004-09-20 WO PCT/US2004/031248 patent/WO2005028434A2/en active Search and Examination
- 2004-09-20 AU AU2004274507A patent/AU2004274507B2/en not_active Ceased
- 2004-09-20 EP EP04788954A patent/EP1670802A4/en not_active Withdrawn
- 2004-09-20 US US10/946,645 patent/US7138401B2/en active Active
- 2004-09-20 US US10/946,637 patent/US7148228B2/en active Active
- 2004-09-20 US US10/945,851 patent/US7138402B2/en active Active
- 2004-09-20 EP EP09157018A patent/EP2145888A1/en not_active Withdrawn
- 2004-09-20 CA CA002539548A patent/CA2539548A1/en not_active Abandoned
- 2004-09-20 JP JP2006527162A patent/JP2007505933A/ja not_active Ceased
- 2004-09-20 US US10/946,628 patent/US7129244B2/en active Active
- 2004-09-20 MX MXPA06002997A patent/MXPA06002997A/es active IP Right Grant
- 2004-09-20 EA EA200600594A patent/EA010160B1/ru not_active IP Right Cessation
- 2004-09-20 BR BRPI0414533-0A patent/BRPI0414533A/pt not_active IP Right Cessation
- 2004-09-20 CN CN2010101575972A patent/CN101906106A/zh active Pending
- 2004-09-20 NZ NZ546611A patent/NZ546611A/en not_active IP Right Cessation
-
2006
- 2006-03-16 IL IL174375A patent/IL174375A0/en unknown
- 2006-03-27 NO NO20061396A patent/NO20061396L/no not_active Application Discontinuation
- 2006-09-12 US US11/531,221 patent/US20070185064A1/en not_active Abandoned
- 2006-09-12 US US11/531,218 patent/US20070173483A1/en not_active Abandoned
- 2006-09-29 US US11/537,017 patent/US20070111997A1/en not_active Abandoned
- 2006-09-29 US US11/537,002 patent/US20070111996A1/en not_active Abandoned
-
2010
- 2010-06-30 AU AU2010202750A patent/AU2010202750B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
AU2010202750B2 (en) | 2011-09-01 |
NZ546611A (en) | 2010-02-26 |
EA010160B1 (ru) | 2008-06-30 |
IL174375A0 (en) | 2006-08-01 |
CN101906106A (zh) | 2010-12-08 |
US20070111996A1 (en) | 2007-05-17 |
AU2004274507B2 (en) | 2010-08-19 |
US20050113339A1 (en) | 2005-05-26 |
AU2010202750A1 (en) | 2010-07-22 |
US20050113340A1 (en) | 2005-05-26 |
US7148228B2 (en) | 2006-12-12 |
CA2539548A1 (en) | 2005-03-31 |
US20050119282A1 (en) | 2005-06-02 |
US7138401B2 (en) | 2006-11-21 |
US7129244B2 (en) | 2006-10-31 |
US20050107343A1 (en) | 2005-05-19 |
EP1670802A2 (en) | 2006-06-21 |
WO2005028434A2 (en) | 2005-03-31 |
NO20061396L (no) | 2006-06-16 |
US20070185064A1 (en) | 2007-08-09 |
MXPA06002997A (es) | 2007-02-08 |
US20070173483A1 (en) | 2007-07-26 |
WO2005028434A3 (en) | 2006-03-23 |
JP2007505933A (ja) | 2007-03-15 |
US7138402B2 (en) | 2006-11-21 |
US20070111997A1 (en) | 2007-05-17 |
BRPI0414533A (pt) | 2006-11-07 |
EP1670802A4 (en) | 2010-07-07 |
EA200600594A1 (ru) | 2006-10-27 |
AU2004274507A1 (en) | 2005-03-31 |
EP2145888A1 (en) | 2010-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20060070572A (ko) | Hsp90-저해제로서의 신규 헤테로시클릭 화합물 | |
AU2002343604C1 (en) | Purine analogs having HSP90-inhibiting activity | |
US20080096903A1 (en) | Sulfamoyl-containing derivatives and uses thereof | |
US20070253896A1 (en) | 7,9-Dihydro-Purin-8-One and Related Analogs as HSP90-Inhibitors | |
NZ561939A (en) | Alkynyl pyrrolopyrimidines and related analogs as HSP90-inhibitors | |
WO1998042711A1 (fr) | DERIVES [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINIQUES | |
Rao et al. | An assessment study of known pyrazolopyrimidines: Chemical methodology and cellular activity | |
US7615558B2 (en) | 6-arylmethylprazolo[3,4-d]pyrimidines | |
CA2344828A1 (en) | ¬1,2,4|triazolo¬1,5-c|pyrimidine derivatives | |
US20080242661A1 (en) | Novel compounds useful for the treatment of degenerative & inflammatory diseases | |
JP2009521446A (ja) | 熱ショックタンパク質90の経口活性なプリンベースの阻害剤 | |
Van Hoof et al. | Identification of novel chemotypes as CXCR2 antagonists via a scaffold hopping approach from a thiazolo [4, 5-d] pyrimidine | |
ZA200602786B (en) | Novel heterocyclic compounds as HSP90-inhibitors | |
Shamroukh et al. | Synthesis of some N-Acyclic Pyrazolopyrimidine Nucleosides and Pyrazolotriazolopyrimidines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E90F | Notification of reason for final refusal | ||
E601 | Decision to refuse application |